Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 15.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 136,599 shares of the biopharmaceutical company’s stock after selling 25,800 shares during the period. Los Angeles Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $3,188,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Rothschild Investment LLC grew its position in shares of Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,520 shares in the last quarter. Advisory Services Network LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth approximately $39,000. Quarry LP acquired a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth approximately $40,000. Clearstead Advisors LLC grew its position in shares of Catalyst Pharmaceuticals by 192.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 1,167 shares in the last quarter. Finally, Financial Life Planners acquired a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth approximately $42,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several research reports. Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $31.50 in a research report on Friday, May 8th. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Finally, Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX opened at $31.34 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $32.56. The firm has a market capitalization of $3.84 billion, a P/E ratio of 18.01, a P/E/G ratio of 0.95 and a beta of 0.74. The business has a 50 day simple moving average of $28.74 and a 200 day simple moving average of $25.47.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).